SGLT2i in CKD with high albuminuria: an observational real-world study

被引：0
|
作者：
Svensson, Maria K. [1 ]
Bodegard, Johan [2 ]
Thuresson, Marcus [3 ]
Ambery, Philip [2 ]
机构：
[1] Uppsala Univ, Uppsala, Sweden
[2] AstraZeneca, Gothenburg, Sweden
[3] Statisticon AB, Uppsala, Sweden
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2024年 / 39卷
关键词：
D O I：
10.1093/ndt/gfae069.147
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
2638
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Finerenone in Patients with CKD and T2D by SGLT2i Treatment: An Analysis of the FIDELIO-DKD Study
    Rossing, Peter
    Agarwal, Rajiv
    Anker, Stefan
    Filippatos, Gerasimos
    Pitt, Bertram
    Ruilope, Luis M.
    Chan, Juliana C.
    Kooy, Adriaan
    Mccafferty, Kieran
    Schernthaner, Guntram
    Wanner, Christoph
    Joseph, Amer
    Scheerer, Markus F.
    Scott, Charlie
    Bakris, George
    DIABETES, 2021, 70
  • [32] Efficacy, renal safety and tolerability of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes: A real-world experience
    Tumminia, Andrea
    Graziano, Marco
    Vinciguerra, Federica
    Lomonaco, Andrea
    Frittita, Lucia
    PRIMARY CARE DIABETES, 2021, 15 (02) : 283 - 288
  • [33] SGLT2i treatment at the beginning of real time exposure in a HFrEF population
    Vintila, V.
    Ciocanel, A.
    Stamate, E.
    Vintila, A. M.
    Vinereanu, D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 251 - 251
  • [34] Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study
    Knudsen, Jakob S.
    Baggesen, Lisbeth M.
    Lajer, Maria
    Nurkanovic, Larisa
    Ustyugova, Anastasia
    Sorensen, Henrik T.
    Thomsen, Reimar W.
    PLOS ONE, 2020, 15 (03):
  • [35] Combined therapy with SGLT2i and GLP-1ra improves cardiovascular prognosis in a population with diabetes and overweigh or obesity. A real-world clinical practice study
    Garcia Vega, D.
    Cinza-Sanjurjo, S.
    Gonzalez-Juanatey, J. R.
    Eiras, S.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [36] SGLT2i and postglomerular vasodilation reply
    van Bommel, Erik J. M.
    van Raalte, Daniel H.
    KIDNEY INTERNATIONAL, 2020, 97 (04) : 806 - 806
  • [37] Seven suggestions for successful SGLT2i use in glomerular disease-a standalone CKD therapy?
    McQuarrie, Emily P.
    Gillis, Keith A.
    Mark, Patrick B.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2022, 31 (03): : 272 - 277
  • [38] Combined sodium-glucose-transporters inhibitors (SGLT2i) and glucagon-like-peptide receptor agonist (GLP1ra) compared with SGLT2i or GLP1ra alone improves survival: a Real-World Registry
    Vega, D. Garcia
    Cinza-Sanjurjo, S.
    Eiras, S.
    Gonzalez-Juanatey, J. R.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [39] SGLT2 inhibitors improve plasma atherogenic biomarkers in patients with type 2 diabetes: a real-world retrospective observational study
    Imre, Eren
    Gunhan, Hatice G.
    Erel, Pinar
    Ustay, Ozlem
    MINERVA ENDOCRINOLOGY, 2023, 48 (03): : 295 - 304
  • [40] Combined sodium-glucose-transporters inhibitors (SGLT2i) and glucagon-like-peptide receptor agonist (GLP1ra) compared with SGLT2i or GLP1ra alone improves survival: a Real-World Registry
    Vega, D. Garcia
    Cinza-Sanjurjo, S.
    Eiras, S.
    Gonzalez-Juanatey, J. R.
    EUROPEAN HEART JOURNAL, 2024, 45
12345